vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and Avantor, Inc. (AVTR). Click either name above to swap in a different company.
Avantor, Inc. is the larger business by last-quarter revenue ($1.7B vs $148.0K, roughly 11240.5× ASTROTECH Corp). Avantor, Inc. runs the higher net margin — 3.1% vs -2653.4%, a 2656.5% gap on every dollar of revenue. On growth, Avantor, Inc. posted the faster year-over-year revenue change (-1.4% vs -43.3%). Avantor, Inc. produced more free cash flow last quarter ($117.2M vs $-4.0M). Over the past eight quarters, ASTROTECH Corp's revenue compounded faster (72.0% CAGR vs -0.5%).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania. Established in 1904 as J.T. Baker, the company changed its name to Avantor in 2010. Avantor went public in 2019 and is now listed on the New York Stock Exchange under the symbol “AVTR”.
ASTC vs AVTR — Head-to-Head
Income Statement — Q2 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $1.7B |
| Net Profit | $-3.9M | $52.4M |
| Gross Margin | 5.4% | 31.5% |
| Operating Margin | -2635.8% | 7.6% |
| Net Margin | -2653.4% | 3.1% |
| Revenue YoY | -43.3% | -1.4% |
| Net Profit YoY | 2.0% | -89.5% |
| EPS (diluted) | — | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | $1.7B | ||
| Q3 25 | $297.0K | $1.6B | ||
| Q2 25 | $220.0K | $1.7B | ||
| Q1 25 | $534.0K | $1.6B | ||
| Q4 24 | $261.0K | $1.7B | ||
| Q3 24 | $34.0K | $1.7B | ||
| Q2 24 | $74.0K | $1.7B | ||
| Q1 24 | $50.0K | $1.7B |
| Q4 25 | $-3.9M | $52.4M | ||
| Q3 25 | $-3.5M | $-711.8M | ||
| Q2 25 | $-2.9M | $64.7M | ||
| Q1 25 | $-3.6M | $64.5M | ||
| Q4 24 | $-4.0M | $500.4M | ||
| Q3 24 | $-3.3M | $57.8M | ||
| Q2 24 | $-3.0M | $92.9M | ||
| Q1 24 | $-3.2M | $60.4M |
| Q4 25 | 5.4% | 31.5% | ||
| Q3 25 | 63.3% | 32.4% | ||
| Q2 25 | 33.6% | 32.9% | ||
| Q1 25 | 44.4% | 33.8% | ||
| Q4 24 | 59.4% | 33.4% | ||
| Q3 24 | 26.5% | 32.9% | ||
| Q2 24 | 37.8% | 34.1% | ||
| Q1 24 | 16.0% | 34.0% |
| Q4 25 | -2635.8% | 7.6% | ||
| Q3 25 | -1190.6% | -40.0% | ||
| Q2 25 | -1326.4% | 7.7% | ||
| Q1 25 | -724.2% | 9.3% | ||
| Q4 24 | -1655.6% | 37.8% | ||
| Q3 24 | -10670.6% | 7.3% | ||
| Q2 24 | -4518.9% | 10.3% | ||
| Q1 24 | -7066.0% | 8.7% |
| Q4 25 | -2653.4% | 3.1% | ||
| Q3 25 | -1166.7% | -43.8% | ||
| Q2 25 | -1331.8% | 3.8% | ||
| Q1 25 | -680.3% | 4.1% | ||
| Q4 24 | -1536.0% | 29.7% | ||
| Q3 24 | -9641.2% | 3.4% | ||
| Q2 24 | -3998.6% | 5.5% | ||
| Q1 24 | -6308.0% | 3.6% |
| Q4 25 | — | $0.08 | ||
| Q3 25 | — | $-1.04 | ||
| Q2 25 | — | $0.09 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.73 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $0.14 | ||
| Q1 24 | — | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $365.4M |
| Total DebtLower is stronger | — | $3.9B |
| Stockholders' EquityBook value | $15.5M | $5.6B |
| Total Assets | $19.7M | $11.8B |
| Debt / EquityLower = less leverage | — | 0.71× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $365.4M | ||
| Q3 25 | $11.3M | $251.9M | ||
| Q2 25 | $15.1M | $449.4M | ||
| Q1 25 | $18.1M | $315.7M | ||
| Q4 24 | $21.5M | $261.9M | ||
| Q3 24 | $21.8M | $285.3M | ||
| Q2 24 | $42.9M | $272.6M | ||
| Q1 24 | $52.4M | $234.9M |
| Q4 25 | — | $3.9B | ||
| Q3 25 | — | $3.9B | ||
| Q2 25 | — | $4.2B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.9B | ||
| Q2 24 | — | $5.1B | ||
| Q1 24 | — | $5.3B |
| Q4 25 | $15.5M | $5.6B | ||
| Q3 25 | $19.1M | $5.6B | ||
| Q2 25 | $22.1M | $6.3B | ||
| Q1 25 | $24.8M | $6.1B | ||
| Q4 24 | $28.1M | $6.0B | ||
| Q3 24 | $32.1M | $5.6B | ||
| Q2 24 | $34.8M | $5.4B | ||
| Q1 24 | $37.6M | $5.3B |
| Q4 25 | $19.7M | $11.8B | ||
| Q3 25 | $23.2M | $11.7B | ||
| Q2 25 | $27.0M | $12.8B | ||
| Q1 25 | $27.5M | $12.3B | ||
| Q4 24 | $31.0M | $12.1B | ||
| Q3 24 | $34.4M | $12.8B | ||
| Q2 24 | $37.6M | $12.7B | ||
| Q1 24 | $40.2M | $12.8B |
| Q4 25 | — | 0.71× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.67× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.94× | ||
| Q1 24 | — | 1.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $152.7M |
| Free Cash FlowOCF − Capex | $-4.0M | $117.2M |
| FCF MarginFCF / Revenue | -2671.6% | 7.0% |
| Capex IntensityCapex / Revenue | 277.7% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 2.91× |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | $495.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | $152.7M | ||
| Q3 25 | $-3.9M | $207.4M | ||
| Q2 25 | $-2.4M | $154.4M | ||
| Q1 25 | $-3.9M | $109.3M | ||
| Q4 24 | $-3.0M | $173.3M | ||
| Q3 24 | $-3.7M | $244.8M | ||
| Q2 24 | $-2.5M | $281.1M | ||
| Q1 24 | $-2.3M | $141.6M |
| Q4 25 | $-4.0M | $117.2M | ||
| Q3 25 | $-4.4M | $171.7M | ||
| Q2 25 | $-2.7M | $124.8M | ||
| Q1 25 | $-3.9M | $81.3M | ||
| Q4 24 | $-3.4M | $145.8M | ||
| Q3 24 | $-3.9M | $204.0M | ||
| Q2 24 | $-2.8M | $235.3M | ||
| Q1 24 | $-2.5M | $106.9M |
| Q4 25 | -2671.6% | 7.0% | ||
| Q3 25 | -1476.1% | 10.6% | ||
| Q2 25 | -1231.4% | 7.4% | ||
| Q1 25 | -728.1% | 5.1% | ||
| Q4 24 | -1288.5% | 8.6% | ||
| Q3 24 | -11408.8% | 11.9% | ||
| Q2 24 | -3728.4% | 13.8% | ||
| Q1 24 | -5036.0% | 6.4% |
| Q4 25 | 277.7% | 2.1% | ||
| Q3 25 | 150.8% | 2.2% | ||
| Q2 25 | 158.2% | 1.8% | ||
| Q1 25 | 5.1% | 1.8% | ||
| Q4 24 | 122.2% | 1.6% | ||
| Q3 24 | 567.6% | 2.4% | ||
| Q2 24 | 305.4% | 2.7% | ||
| Q1 24 | 352.0% | 2.1% |
| Q4 25 | — | 2.91× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 1.69× | ||
| Q4 24 | — | 0.35× | ||
| Q3 24 | — | 4.24× | ||
| Q2 24 | — | 3.03× | ||
| Q1 24 | — | 2.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTC
Segment breakdown not available.
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
